GOVERNANCE AT THE THRESHOLD / FAQ
A few questions.
Clear answers.
Why this period? Why these companies? What can the findings tell us? Open a question to find out.
01 / THE STUDY
About the research
What is this research about, in one sentence?
Are biotech companies with more investor representatives on their boards at IPO acquired sooner afterwards?
What did you find?
In North America, a 20.7-percentage-point higher investor share of board seats was associated with about 1.5× the acquisition rate among companies still at risk. After accounting for disclosed investor ownership, the estimate fell to 1.3× and was not robust across reasonable checks. Whether board seats add reliable information beyond ownership remains unresolved.
Why study companies that listed between 2015 and 2021?
This period provides a sizeable group of biotech listings, with several years to observe what happened afterwards. The frame has 452 companies: 349 in North America and 103 in Europe. The listing window ends in 2021; outcomes are followed through 25 September 2026.
Why use SEC filings?
They are public documents that name directors, major shareholders and the connections between them. The ownership footnotes help establish which investor a director represents. SEC filings cover the US-listed companies; European home-listed companies required other sources.
Why study listed companies rather than private ones?
The question concerns what happens after an IPO. Listing provides a common starting point and detailed disclosures. Private companies, and companies acquired before completing an IPO, fall outside this study.
Why focus on biotechnology?
Developing medicines takes years and substantial funding. Investors may remain involved after listing, and acquisition is an important possible outcome. This makes biotech a useful setting for studying investor directors.
Why measure the board at IPO?
It captures the board at a common milestone, before the later outcome occurs. It also examines a moment when many special investor rights lapse, while board seats may remain. It does not track every subsequent board change.
What counts as an investor director?
A director needs a documented connection to an institutional investor holding shares in the company. Having worked in investment in the past is not enough. Written rules distinguish investor representatives, insiders and other directors.
How were the boards checked?
The 3,158 seats were coded under written rules, principally from listing documents. A separate AI coding pass checked consistency, and disagreements were reconciled against the documents. Three hand checks covered 160 boards, including 120 checked blind. Repeated AI coding checks consistency; it is not independent human validation.
Why examine ownership as well as board seats?
More seats may simply reflect a larger shareholding. Including disclosed ownership tests whether board representation adds information beyond the shares investors hold. That additional information is not robustly established here.
Why distinguish acquisition, failure and reverse merger?
They represent different outcomes. A buyer acquiring the biotech business differs from a private company taking over its stock-market listing. Delisting alone also does not establish that the business failed.
Does “1.5× acquisition hazard” mean a 50% chance of being acquired?
No. It describes a relative acquisition rate among companies still at risk, per 20.7-percentage-point increase in investor board share. On a typical seven-seat board, 20.7 points is about one and a half extra investor directors. It is not an individual probability or a prediction of months saved.
Does the study prove investor directors cause acquisitions?
No. Investors may influence decisions, select companies already likely to attract buyers, or both. The study identifies an association; it cannot settle the cause.
Did investor-heavy boards get a better price when they sold?
Among 90 acquisitions with price data, no statistically detectable association was found between investor board share and measured acquisition premiums. This does not establish that prices were equal or fair.
Why include Europe if North America is the main analysis?
Europe provides a comparison of board structures and listing routes. Its coverage is less complete and acquisitions are fewer, so the European extension is descriptive rather than a decisive replication.
Does the study cover every biotech IPO?
It covers an assembled frame defined by industry codes, geography, listing dates and eligibility rules. It does not represent every biotech IPO worldwide.
Can I see the data?
The thesis and its annexes describe every source and step. Some data come from licensed databases, so the raw files cannot be shared.
Is this investment advice?
No. It is academic research about past listings, not a guide to buying or selling shares.
02 / THE COMPANION
About this website
Is this the thesis?
No, it is a companion to it. The thesis submitted to ESCP is the full, official version. If anything here differs, the thesis is right.
Is this an official ESCP website?
No. It is a personal project by the author. The thesis was written at ESCP Business School under the supervision of Julie Rachline.
What are Beach and Library modes?
Beach mode is the quick, plain-language version of each chapter. Library mode goes deeper and stays closer to the thesis text. You can switch at any time.
What are the coins and the quiz for?
Just for fun. Guess before you read and see how you do. Your progress is kept only in your own browser and is not sent anywhere.
Where are the artwork credits?
On the Sources and credits page.
Who made this?
See About the author.